- Home
- RFAI vs IKT Comparison
RFAI vs IKT Comparison
Compare RFAI & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFAI
- IKT
- Stock Information
- Founded
- RFAI 2024
- IKT 2008
- Country
- RFAI Singapore
- IKT United States
- Employees
- RFAI N/A
- IKT N/A
- Industry
- RFAI
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- RFAI
- IKT Health Care
- Exchange
- RFAI NYSE
- IKT Nasdaq
- Market Cap
- RFAI 153.0M
- IKT 159.2M
- IPO Year
- RFAI 2024
- IKT 2020
- Fundamental
- Price
- RFAI $10.25
- IKT $2.72
- Analyst Decision
- RFAI
- IKT Strong Buy
- Analyst Count
- RFAI 0
- IKT 2
- Target Price
- RFAI N/A
- IKT $6.50
- AVG Volume (30 Days)
- RFAI 19.6K
- IKT 288.1K
- Earning Date
- RFAI 01-01-0001
- IKT 11-14-2024
- Dividend Yield
- RFAI N/A
- IKT N/A
- EPS Growth
- RFAI N/A
- IKT N/A
- EPS
- RFAI N/A
- IKT N/A
- Revenue
- RFAI N/A
- IKT $1.00
- Revenue This Year
- RFAI N/A
- IKT N/A
- Revenue Next Year
- RFAI N/A
- IKT N/A
- P/E Ratio
- RFAI N/A
- IKT N/A
- Revenue Growth
- RFAI N/A
- IKT N/A
- 52 Week Low
- RFAI $10.25
- IKT $1.12
- 52 Week High
- RFAI $10.27
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- RFAI N/A
- IKT 41.71
- Support Level
- RFAI N/A
- IKT $2.55
- Resistance Level
- RFAI N/A
- IKT $2.90
- Average True Range (ATR)
- RFAI 0.00
- IKT 0.29
- MACD
- RFAI 0.00
- IKT -0.08
- Stochastic Oscillator
- RFAI 0.00
- IKT 18.09
About RFAI RF ACQUISITION CORP II
RF Acquisition Corp II is a blank check company.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.